User:Biomedjill/Elexacaftor/tezacaftor/ivacaftor

From Wikipedia, the free encyclopedia

Elexacaftor/tezacaftor/ivacaftor, sold under the brand names Trikafta (US) and Kaftrio (Europe), is a fixed-dose combination medication used with adults and children older than age 6 that have cystic fibrosis with a f508del mutation or other mutations.[1] Patients with cystic fibrosis have thicker mucus secretions due to genetic mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) protein which inhibits the transfer of chloride and sodium ions from cells. Elexacaftor/tezacaftor/ivacaftor is composed of a combination of ivacaftor, a chloride channel opener, and elexacaftor and tezacaftor, CFTR modulators.[1]

It is approved use in the United States for people aged 6 years of age or older with with the f508del mutation or 177 other cystic fibrosis mutations.[2] It is also approved for use in Canada, the European Union and Australia.[3][4][5]

Biomedjill/Elexacaftor/tezacaftor/ivacaftor
Combination of
ElexacaftorCystic fibrosis transmembrane conductance regulator (CFTR) corrector
TezacaftorCFTR corrector
IvacaftorChloride channel opener
Clinical data
Trade namesTrikafta, Kaftrio
AHFS/Drugs.comMonograph
MedlinePlusa619061
License data
Pregnancy
category
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG

Cystic Fibrosis and CFTR[edit]

Cystic fibrosis is an autosomal recessive genetic disorder of the CFTR protein which reduces chloride and sodium ion transport through the cell membrane, causing thicker than normal mucus secretions.[10][11] The CFTR protein is found in epithelial cells of the lung, liver, pancreas, digestive tract, and reproductive tracts.[12][13][14] CFTR has a role in the production of mucus, sweat, and digestive fluids.[15] The thickened mucus can lead to inflammation, respiratory infections, and clogged ducts.[16][17][18]

Pharmacology[edit]

Effects[edit]

A phase III trial showed people treated with elexacaftor/tezacaftor/ivacaftor improved in FEV1 at four weeks with sustained improvement at 24 weeks. Rate of pulmonary exacerbation was 63% lower and sweat chloride concentration was 41.8 mmol/L lower.[19][20][21] It's effectiveness is dependent on the type of CF mutations the patient has.[22]

Mechanism of Action[edit]

Elexacaftor/tezacaftor/ivacaftor is a tridrug treatment in which the medications work together to increase the transport of chloride and sodium ions, and reducing thick mucus production.[23]

Complex of ivacaftor with CFTR
CFTR Channel Potentiator[edit]
ivacaftor

Ivacaftor is a selective small-molecule potentiator of the CFTR protein that increases the protein's ability to open chloride channels.[24][25] Its effectiveness is highly dependent on the amount of CFTR protein at the cell surface and the responsiveness of the mutant CFTR protein.[26] Ivacaftor's primary target is to treat class III CFTR gating mutations like G551D as well as other less common mutations.[25] In the crystalline figure, you can see ivacaftor, shown as a gray ball and stick model on the bottom-right, bound to CFTR docked in a cleft formed by transmembrane helices at the protein-lipid interface.[27]

elexacaftor
CFTR Correctors[edit]

Elexacaftor and Tezacaftor act as CFTR correctors to repair F508del processing by binding to the CFTR protein to increase the availability of CFTR protein on the cell surface.[25] They work by modulating the position of the CFTR protein into the right position on the cell surface.[28]

tezacaftor

The combination of increased CFTR protein in the correct position on the cell surface with ivacaftor's potentiation of chloride channel opening results in increased transport of chloride and thinned mucus secretions.[25]

Daily recommended dosage of Trikafta. Two combination Elexacaftor, Tezacaftor, Ivacaftor tablets and one ivacaftor tablet

Formulations[edit]

Trikafta utilizes a combination tablet containing 100 mg of elexacaftor, 50 mg of tezacaftor, and 75 mg of ivacaftor, and a separate tablet containing 150mg of ivacaftor.[29]

Recommended Dosage[edit]

The morning dose is two combination tablets containing elexacaftor 100 mg, tezacaftor 50 mg and ivacaftor 75 mg. The evening dose is one ivacaftor 150mg tablet.[30]

Side/Adverse Effects[edit]

The most common side effects affecting more than 5% of patients are headache, upper respiratory tract infection, abdominal pain, diarrhea, rash, alanine aminotransferase increased, nasal congestion, blood creatine phosphokinase increased, aspartate aminotransferase increased, rhinorrhea, rhinitis, influenza, sinusitis and blood bilirubin increased.[31][32]

Interactions[edit]

Concomitant use with CYP3A inducers is not recommended.[33][34] Dosage must be adjusted with moderate or strong CYP3A inhibitors.[34][33]

Other drugs with the potential for interaction include: warfarin, digoxin, statins, glyburide, nateglinide, repaglinide.[34][33]

Pharmacokinetics[edit]

Elexacaftor/tezacaftor/ivacaftor is primarily metabolized by CYP3A4/5. This medication should be taken with a high fat meal to improve absorption through the gut. [35] It is excreted as metabolites or unchanged mainly through feces and to a smaller extent urine. The mean effective half-life of elexacaftor, tezacaftor, and ivacaftor is 27.4 hours, 25.1 hours, and 15 hours, respectively. [31]

Research[edit]

Human Studies/Trials
Trial Type Primary Endpoint Target age Target Mutations Results References
Trial 1 A placebo-controlled trial in patients heterozygous for the F508del mutation and another specific mutation • Absolute change in ppFEV1 from baseline at Week 4 People aged 12 years and older • Heterozygous for the F508del mutation and one of ~200 other mutations in the CFTR gene that resulted in either: - No CFTR protein - A CFTR protein that lacks baseline activity and is not responsive to ivacaftor and tezacaftor/ivacaftor • ppFEV1 between 40% to 90% at screening percentage of predicted FEV1 that was 13.8 points higher at 4 weeks and 14.3 points higher through 24 weeks [36][37]
Trial 2 A double-blind, active-controlled, phase 3 study • Absolute change in ppFEV1 from baseline at Week 4 People aged 12 years and older Homozygous for the F508del mutation Elexacaftor/tezacaftor/ivacaftor showed improvements in percent predicted forced expiratory volume (ppFEV1) over patients receiving tezacaftor/ivacaftor [38]
Trial 3 Open label study with no placebo control Safety, pharmacokinetics and efficacy Children aged 6-11 Homozygous for the F508del mutation OR

- Heterozygous for the F508del mutation and one of ~200 other mutations in the

CFTR gene that resulted in either:

• No CFTR protein

• A CFTR protein that lacks baseline activity and is not responsive to ivacaftor and

tezacaftor/ivacaftor

safety and pharmacokinetic profiles were generally consistent with those observed in older patients [39]

CFTR mutations that are responsive to elexacaftor/tezacaftor/ivacaftor were determined by an in-vitro study of Fischer Rat Thyroid (FRT) cells that expressed mutant CFTR. Elexacaftor/tezacaftor/ivacaftor showed effectiveness with mutations where the CFTR protein was being successfully delivered to the cell surface.[1]

Society & Culture[edit]

Legal Status[edit]

United States[edit]

The combination was approved for use in the United States in 2019 for people twelve years and older with cystic fibrosis who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which is estimated to represent 90% of the cystic fibrosis population.[40] In December 2020, after an additional clinical trial was completed, and FDA approval was expanded for 177 other cystic fibrosis mutations.[2] FDA approval for children aged 6-11 was added in January 2021 after third clinical trial was completed.[41]

The U.S. Food and Drug Administration (FDA) granted the application priority review, in addition to fast track, breakthrough therapy, and orphan drug designations. The drug's manufacturer Vertex Pharmaceuticals will receive a rare pediatric disease priority review voucher for having developed this therapy.[42]

Australia[edit]

On March 30, 2021 health regulators in Australia approved trikafta for patients aged 12 years and older with at least one copy of the F508del mutation.[43]

Canada[edit]

In June of 2020, Health Canada approved Trikafta for patients ages 12 and up.[44] In September 2021, the provinces Alberta and Saskatchewan announced they will join Ontario in funding the medication. They will determine coverage on a case-by-case basis using a criteria that has not yet been announced.[45]

European Union[edit]

In June 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended its approval for the treatment of cystic fibrosis.[46][47] It was approved for medical use in the European Union in August 2020.[9]

Cost[edit]

The list price of a year's treatment in the US is US$311,000.[48] However, a 2020 report by Institute for Clinical and Economic Review found that the price has made the treatment not cost effective and that "an appropriate health-benefit price would range from $67,900–$85,500 per year".[49][50]

Spain[edit]

On November 19, 2021 the Spanish government approved the reimbursement of KAFTRIO (ivacaftor/tezacaftor/elexacaftor) for patients ages 12 and older with at least one copy of the F508del mutation.[51]

References[edit]

  1. ^ a b c d "Trikafta- elexacaftor, tezacaftor, and ivacaftor kit". DailyMed. 29 January 2020. Retrieved 22 August 2020.
  2. ^ a b Bethesda, Cystic Fibrosis Foundation 4550 Montgomery Ave Suite 1100 N.; Md 20814301-951-4422 800-344-4823. "FDA Approves Expansion of Modulators for People With Certain Rare Mutations". www.cff.org. Retrieved 2021-10-03.{{cite web}}: CS1 maint: numeric names: authors list (link)
  3. ^ "Kaftrio EPAR". European Medicines Agency (EMA). 23 June 2020. Retrieved 21 August 2020.
  4. ^ MS, Marisa Wexler. "Health Canada Approves Trikafta for Eligible CF Patients, 12 and Up". Retrieved 2021-11-08.
  5. ^ Administration, Australian Government Department of Health Therapeutic Goods (2021-07-08). "AusPAR: Elexacaftor/tezacaftor/ivacaftor and ivacaftor". Therapeutic Goods Administration (TGA). Retrieved 2021-11-28.
  6. ^ a b "Trikafta". Therapeutic Goods Administration (TGA). 8 April 2021. Retrieved 8 September 2021.
  7. ^ a b "AusPAR: Elexacaftor/tezacaftor/ivacaftor and ivacaftor". Therapeutic Goods Administration (TGA). 8 July 2021. Retrieved 8 September 2021.
  8. ^ MS, Marisa Wexler. "CF Therapy Trikafta Now Covered in 2 More Canadian Provinces". Retrieved 2021-11-08.
  9. ^ a b "Kaftrio EPAR". European Medicines Agency (EMA). 23 June 2020. Retrieved 21 August 2020.
  10. ^ O'Sullivan BP, Freedman SD (May 2009). "Cystic fibrosis". Lancet. 373 (9678): 1891–904. doi:10.1016/s0140-6736(09)60327-5. PMID 19403164. S2CID 46011502.
  11. ^ Hodson M, Geddes D, Bush A, eds. (2012). Cystic Fibrosis (3rd ed.). London: Hodder Arnold. p. 3. ISBN 978-1-4441-1369-3. Archived from the original on 8 September 2017.
  12. ^ Sharma S, Hanukoglu I (April 2019). "Mapping the sites of localization of epithelial sodium channel (ENaC) and CFTR in segments of the mammalian epididymis". Journal of Molecular Histology. 50 (2): 141–154. doi:10.1007/s10735-019-09813-3. PMID 30659401. S2CID 58026884.
  13. ^ Sharma S, Hanukoglu A, Hanukoglu I (April 2018). "Localization of epithelial sodium channel (ENaC) and CFTR in the germinal epithelium of the testis, Sertoli cells, and spermatozoa". Journal of Molecular Histology. 49 (2): 195–208. doi:10.1007/s10735-018-9759-2. PMID 29453757. S2CID 3761720.
  14. ^ Enuka Y, Hanukoglu I, Edelheit O, Vaknine H, Hanukoglu A (March 2012). "Epithelial sodium channels (ENaC) are uniformly distributed on motile cilia in the oviduct and the respiratory airways". Histochemistry and Cell Biology. 137 (3): 339–53. doi:10.1007/s00418-011-0904-1. PMID 22207244. S2CID 15178940.
  15. ^ Buckingham L (2012). Molecular Diagnostics: Fundamentals, Methods and Clinical Applications (2nd ed.). Philadelphia: F.A. Davis Co. p. 351. ISBN 978-0-8036-2975-2. Archived from the original on 8 September 2017.
  16. ^ Flume PA, Mogayzel PJ, Robinson KA, Rosenblatt RL, Quittell L, Marshall BC (August 2010). "Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax". American Journal of Respiratory and Critical Care Medicine. 182 (3): 298–306. doi:10.1164/rccm.201002-0157OC. PMID 20675678.
  17. ^ Mitchell RS, Kumar V, Robbins SL, et al. (2007). Robbins Basic Pathology. Saunders/Elsevier. p. 1253, 1254. ISBN 978-1-4160-2973-1.
  18. ^ Mitchell RS, Kumar V, Robbins SL, et al. (2007). Robbins Basic Pathology. Saunders/Elsevier. p. 1253, 1254. ISBN 978-1-4160-2973-1.
  19. ^ Middleton PG, Mall MA, Dřevínek P, et al. (VX17-445-102 Study Group) (October 2019). "Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele". N. Engl. J. Med. 381 (19): 1809–19. doi:10.1056/NEJMoa1908639. ISSN 0028-4793. PMC 7282384. PMID 31697873.
  20. ^ Taylor-Cousar JL, Mall MA, Ramsey BW, et al. (April 2019). "Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles". ERJ Open Res. 5 (2): 00082–2019. doi:10.1183/23120541.00082-2019. PMC 6571452. PMID 31218221.
  21. ^ Clinical trial number NCT03525444 for "A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)" at ClinicalTrials.gov
  22. ^ Tice, Jeffrey A; Kuntz, Karen M; Wherry, Kael; Seidner, Matt; Rind, David M; Pearson, Steven D (2021-02-01). "The effectiveness and value of novel treatments for cystic fibrosis". Journal of Managed Care & Specialty Pharmacy. 27 (2): 276–280. doi:10.18553/jmcp.2021.27.2.276. ISSN 2376-0540.
  23. ^ PubChem. "Tezacaftor". pubchem.ncbi.nlm.nih.gov. Retrieved 2021-11-07.
  24. ^ "PharmGKB". PharmGKB. Retrieved 2021-12-09.
  25. ^ a b c d Zaher, Anas; ElSaygh, Jude; Elsori, Dalal; ElSaygh, Hassan; Sanni, Abdulsabar (2021-07-03). "A Review of Trikafta: Triple Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Therapy". Cureus. 13 (7). doi:10.7759/cureus.16144. ISSN 2168-8184.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  26. ^ PubChem. "Ivacaftor". pubchem.ncbi.nlm.nih.gov. Retrieved 2021-11-07.
  27. ^ Liu, Fangyu; Zhang, Zhe; Levit, Anat; Levring, Jesper; Touhara, Kouki K.; Shoichet, Brian K.; Chen, Jue (2019-06-21). "Structural identification of a hotspot on CFTR for potentiation". Science. 364 (6446): 1184–1188. doi:10.1126/science.aaw7611. PMC 7184887. PMID 31221859.{{cite journal}}: CS1 maint: PMC format (link)
  28. ^ PubChem. "Tezacaftor". pubchem.ncbi.nlm.nih.gov. Retrieved 2021-11-07.
  29. ^ "TRIKAFTA". Rxlist. February 8, 2021. Retrieved October 13, 2021.{{cite web}}: CS1 maint: url-status (link)
  30. ^ "TRIKAFTA". Rxlist. February 8, 2021. Retrieved October 13, 2021.{{cite web}}: CS1 maint: url-status (link)
  31. ^ a b Vertex Pharmaceuticals. Trikafta (Elexacaftor/tezacaftor/ivacaftor) [package insert]. U.S. Food and Drug Administration website.https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212273s004lbl.pdf. Revised June 2021. Accessed October 3, 2021.
  32. ^ "Trikafta Side Effects". Drugs.com. January 24, 2021. Retrieved October 3, 2021.{{cite web}}: CS1 maint: url-status (link)
  33. ^ a b c "elexacaftor/tezacaftor/ivacaftor (Rx)". Medscape. Retrieved October 3, 2021.{{cite web}}: CS1 maint: url-status (link)
  34. ^ a b c Vertex Pharmaceuticals. Trikafta (Elexacaftor/tezacaftor/ivacaftor) [package insert]. U.S. Food and Drug Administration website.https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212273s004lbl.pdf. Revised June 2021. Accessed October 3, 2021.
  35. ^ "PharmGKB". PharmGKB. Retrieved 2021-12-09.
  36. ^ Middleton, Peter G.; Mall, Marcus A.; Dřevínek, Pavel; Lands, Larry C.; McKone, Edward F.; Polineni, Deepika; Ramsey, Bonnie W.; Taylor-Cousar, Jennifer L.; Tullis, Elizabeth; Vermeulen, François; Marigowda, Gautham (2019-10-31). "Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele". New England Journal of Medicine. doi:10.1056/NEJMoa1908639. PMC 7282384. PMID 31697873.{{cite journal}}: CS1 maint: PMC format (link)
  37. ^ Lopes-Pacheco, Miquéias (2020). "CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine". Frontiers in Pharmacology. 10: 1662. doi:10.3389/fphar.2019.01662. ISSN 1663-9812.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  38. ^ Heijerman, Harry G. M.; McKone, Edward F.; Downey, Damian G.; Van Braeckel, Eva; Rowe, Steven M.; Tullis, Elizabeth; Mall, Marcus A.; Welter, John J.; Ramsey, Bonnie W.; McKee, Charlotte M.; Marigowda, Gautham (2019-11-23). "Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial". Lancet (London, England). 394 (10212): 1940–1948. doi:10.1016/S0140-6736(19)32597-8. ISSN 1474-547X. PMC 7571408. PMID 31679946.
  39. ^ Zemanick, Edith T.; Taylor-Cousar, Jennifer L.; Davies, Jane; Gibson, Ronald L.; Mall, Marcus A.; McKone, Edward F.; McNally, Paul; Ramsey, Bonnie W.; Rayment, Jonathan H.; Rowe, Steven M.; Tullis, Elizabeth (2021-06-15). "A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele". American Journal of Respiratory and Critical Care Medicine. 203 (12): 1522–1532. doi:10.1164/rccm.202102-0509OC. ISSN 1073-449X. PMC 8483230. PMID 33734030.{{cite journal}}: CS1 maint: PMC format (link)
  40. ^ "FDA approves new breakthrough therapy for cystic fibrosis". U.S. Food and Drug Administration (FDA) (Press release). October 21, 2019. Archived from the original on November 13, 2019. Retrieved November 13, 2019. Public Domain This article incorporates text from this source, which is in the public domain.
  41. ^ Bethesda, Cystic Fibrosis Foundation 4550 Montgomery Ave Suite 1100 N.; Md 20814301-951-4422 800-344-4823. "FDA Accepts Vertex Application for Expansion of Trikafta to Include Children ages 6-11". www.cff.org. Retrieved 2021-10-03.{{cite web}}: CS1 maint: numeric names: authors list (link)
  42. ^ "FDA approves new breakthrough therapy for cystic fibrosis". U.S. Food and Drug Administration (FDA) (Press release). October 21, 2019. Archived from the original on November 13, 2019. Retrieved November 13, 2019. Public Domain This article incorporates text from this source, which is in the public domain.
  43. ^ PhD, Margarida Maia. "Trikafta Approved in Australia for CF Patients Starting at Age 12". Retrieved 2021-11-28.
  44. ^ MS, Marisa Wexler. "Health Canada Approves Trikafta for Eligible CF Patients, 12 and Up". Retrieved 2021-11-08.
  45. ^ MS, Marisa Wexler. "CF Therapy Trikafta Now Covered in 2 More Canadian Provinces". Retrieved 2021-11-08.
  46. ^ "New medicine for cystic fibrosis patients". European Medicines Agency (EMA) (Press release). 26 June 2020. Retrieved 26 June 2020.
  47. ^ "Elexacaftor + ivacaftor + tezacaftor". SPS - Specialist Pharmacy Service. 28 July 2020. Retrieved 21 August 2020.
  48. ^ Maddipatla, Manojna; O'Donnell, Carl (October 21, 2019). "Vertex prices cystic fibrosis combo treatment at $311,000-per-year". Reuters. Retrieved October 23, 2019.
  49. ^ PhD, Ines Martins. "Trikafta Very Effective CF Therapy, But Still Too Costly, ICER Reports". Retrieved 2020-08-21.
  50. ^ "Modulator Treatments for Cystic Fibrosis: Effectiveness and Value" (PDF). Institute for Clinical and Economic Review. Institute for Clinical and Economic Review. 27 April 2020. Retrieved 21 August 2020.
  51. ^ "Vertex Announces Reimbursement Agreement in Spain for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis 12 Years and Older With At Least One F508del Mutation in the CFTR Gene - ANSA.it". www.ansa.it. Retrieved 2021-11-28.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Biomedjill/Elexacaftor/tezacaftor/ivacaftor&oldid=1059366315"